Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- University of Texas Health Science Center at Houston
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Transendocardial
01
Overview
This investigational cell therapy consists of allogeneic bone marrow-derived mesenchymal stromal cells (allo-MSCs) being evaluated for the treatment of anthracycline-induced cardiomyopathy (AIC) in cancer survivors. Developed by The University of Texas Health Science Center, Houston, and studied in the Phase I SENECA trial, the therapy involves the transendocardial injection of 100 million cells. The biological mechanism is primarily paracrine, involving the secretion of factors that modulate fibrosis, apoptosis, and inflammation within the myocardium. Additionally, the cells are believed to transfer mitochondria-rich extracellular vesicles to damaged cardiomyocytes to restore metabolic function and promote tissue repair.
- Other names
- allogeneic bone marrow-derived mesenchymal stromal cellsallo-MSCs
Beyond the preview
Go deeper on allogeneic mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic mesenchymal stem cells.